Market Closed - Nasdaq 21:00:00 11/09/2024 BST 5-day change 1st Jan Change
80.01 USD -2.38% Intraday chart for Hologic, Inc. -1.97% +11.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nephron Trims Price Target on Hologic to $92 From $95 MT
Transcript : Hologic, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 12:20 PM
Stephens Raises Hologic's Price Target to $95 From $92 MT
Hologic Insider Sold Shares Worth $3,597,924, According to a Recent SEC Filing MT
From Mammograms to Molecules: Hologic's Quest in Women's Health Tech Our Logo
BNP Paribas Exane Adjusts Price Target on Hologic to $96 From $95 MT
Global markets live: Diageo, Apple, Tesla, Meta Platforms, PayPal, Pfizer... Our Logo
UBS Adjusts Hologic Price Target to $84 From $81, Maintains Neutral Rating MT
Evercore ISI Adjusts Hologic Price Target to $78 From $76 MT
JPMorgan Adjusts Hologic Price Target to $95 From $91 MT
Raymond James Adjusts Hologic Price Target to $93 From $88 MT
RBC Raises Price Target on Hologic to $82 From $81, Keeps Sector Perform Rating MT
Hologic quarterly profit rises on strong demand for its women's health products RE
Transcript : Hologic, Inc., Q3 2024 Earnings Call, Jul 29, 2024
Hologic Fiscal Q3 Non-GAAP EPS, Revenue Rise; 2024 Outlook Updated MT
(HOLX) HOLOGIC Forecasts Fiscal Year 2024 EPS Range $4.04 - $4.11 MT
Earnings Flash (HOLX) HOLOGIC Posts Q3 Revenue $1.01B, vs. Street Est of $1B MT
(HOLX) HOLOGIC Forecasts Q4 EPS Range $0.97 - $1.04 MT
Earnings Flash (HOLX) HOLOGIC Posts Q3 EPS $1.06, vs. Street Est of $1.01 MT
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on September 23, 2022. CI
Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 CI
Hologic, Inc. Revises Earnings Guidance for the Full Year 2024 CI
Hologic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 29, 2024 CI
Global markets live: Apple, 3M Company, Boeing, Honeywell... Our Logo
Molten Ventures Finalizes Exit from Endomagnetics MT
Chart Hologic, Inc.
More charts
Logo Hologic, Inc.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Employees
6,990
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
81.96USD
Average target price
87.07USD
Spread / Average Target
+6.23%
Consensus
  1. Stock Market
  2. Equities
  3. HOLX Stock
  4. News Hologic, Inc.
  5. Stephens Raises Hologic's Price Target to $95 From $92
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW